PHASE I STUDY OF TRIAPINE IN COMBINATION WITH DOXORUBICIN IN REFRACTORY TUMORS

Triapine 联合阿霉素治疗难治性肿瘤的 I 期研究

• 批准号: 7607512
• 负责人: GEORGE WILDING
• 金额: $ 0.29万
• 依托单位: UNIVERSITY OF WISCONSIN-MADISON
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-12-01 至 2007-09-16
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7607512
• 关键词: 3-Aminopyridine-2-carboxaldehyde Thiosemicarbazone; Adverse effects; Computer Retrieval of Information on Scientific Projects Database; Dose; Doxorubicin; Drug usage; Enzymes; Funding; Grant; Growth; Institution; Patients; Pharmaceutical Preparations; Phase; Phase I Clinical Trials; Recruitment Activity; Refractory; Research; Research Personnel; Resources; Solid Neoplasm; Source; Triapine; United States National Institutes of Health; Work; cancer cell; cell growth; chemotherapy; killings; neoplastic cell; tumor

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study is no longer recruiting subjects. (from www.ClinicalTrials.gov website) Drugs used in chemotherapy, such as doxorubicin, work in different ways to stop tumor cells from dividing so they stop growing or die. Triapine (3-AP) may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth and may help doxorubicin kill more cancer cells by making them more sensitive to the drug. This Phase I trial is studying the side-effects and best dose of triapine and doxorubicin in treating patients with metastatic or refractory solid tumors.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 本研究不再招募受试者。 (from www.ClinicalTrials.gov网站） 化疗中使用的药物，如阿霉素，以不同的方式阻止肿瘤细胞分裂，使它们停止生长或死亡。三羟甲基氨基甲烷（3-AP）可以通过阻断肿瘤细胞生长所必需的酶来阻止肿瘤细胞的生长，并可以通过使多柔比星对药物更敏感来帮助多柔比星杀死更多的癌细胞。 这项I期临床试验正在研究曲拉唑和阿霉素治疗转移性或难治性实体瘤患者的副作用和最佳剂量。